Josh Brumm

CEO of Crescent, building a world leading oncology company; investor. Passionate about leadership, dedicated to family, proud @NotreDame alum. Opinions my own.

[Josh Brumm @BrummJosh]

Our values are the foundation of everything we do at Crescent. Proud of this team for living them every day — with urgency and a commitment to patients.

[Crescent Biopharma @crescent_bio]

Last week, #TeamCrescent celebrated Core Values Day, bringing employees & families together to reflect on the values that shape how we work, collaborate & deliver for patients.

It was a meaningful opportunity to celebrate the culture that brings us together in a shared mission.

[Josh Brumm @BrummJosh]

Proud to join Team Crescent for this special moment.

Days like this are a reminder of the passion and sense of purpose that drive our work every day, made possible by our team, partners, investigators, and patients.

[Crescent Biopharma @crescent_bio]

We rang the @NasdaqExchange closing bell this week!

An exciting moment for our team & motivation to continue advancing new therapies with the goal of improving outcomes for people living with cancer.

Thank you to our team, partners & the patients who inspire our mission.

$CBIO

[Crescent Biopharma @crescent_bio]

Heading to #ASCO26? We’re looking forward to connecting with colleagues across the oncology community, exchanging ideas, and highlighting our efforts to develop innovative therapies for people living with cancer.

See you in Chicago!

[Josh Brumm @BrummJosh]

When it comes to managing CMC operations, Wenjie has exceptional leadership and expertise. We’re fortunate to have her driving this important work at Crescent.

[Crescent Biopharma @crescent_bio]

Meet Wenjie Cheng, Ph.D., SVP of Technical Operations at Crescent who leads our CMC strategy and manufacturing. With 20+ years of industry experience, she brings deep expertise in antibody and ADC development and production. We’re grateful for her operational leadership!

[Josh Brumm @BrummJosh]

Thank you to the hardworking administrative professionals at Crescent who keep everything moving forward! Your impact is felt across the organization every day and we’re grateful for all that you do.

[Crescent Biopharma @crescent_bio]

Today, on #AdministrativeProfessionalsDay, we’re celebrating the incredible individuals behind the scenes who keep #TeamCrescent running.

Their coordination and dedication to our team helps power the progress behind everything we do for patients.

[Josh Brumm @BrummJosh]

Great progress from Kelun-Biotech in achieving this clinical milestone! We value our partnership and working together to bring therapies that can make a difference for people living with cancer.

[Crescent Biopharma @crescent_bio]

Congratulations to Kelun-Biotech on recently initiating a Phase 1/2 trial of CR-003 (SKB105) in advanced solid tumors in China. Proud to partner in advancing next-gen therapies to improve outcomes for people living with cancer. Learn more about CR-003: https://t.co/tuxBpyhanz

[Josh Brumm @BrummJosh]

Great companies are built by great people, and our exceptional team is central to Crescent’s success. Very proud of our colleagues for their hard work and dedication to delivering for patients!

[Crescent Biopharma @crescent_bio]

On #EmployeeAppreciationDay, we recognize the incredible people at Crescent who make our progress possible. We’re proud of our team’s shared commitment to our mission of delivering the next wave of transformative therapies to bring a brighter future for people living with cancer.

[Josh Brumm @BrummJosh]

A big milestone for our company, and couldn’t have been achieved without the hard work, dedication and collaborative effort from everyone at Crescent! Important step in our efforts to deliver the next wave of transformative therapies for people living with cancer.

[Crescent Biopharma @crescent_bio]

We are excited to announce that the first patient has been dosed in ASCEND, our global Phase 1/2 clinical trial of CR-001, an investigational PD-1 x VEGF bispecific antibody, for the treatment of advanced solid tumors. Learn more in our press release: https://t.co/h3jDnVIKKm

[Crescent Biopharma @crescent_bio]

We will be in San Francisco for #JPM2026 next week! We’re excited about what’s ahead for Crescent and look forward to connecting with the biopharma community on our efforts to deliver the next wave of therapies for people living with cancer.

[Josh Brumm @BrummJosh]

Thrilled to partner with Kelun-Biotech, an established ADC leader that shares our commitment to delivering next generation oncology therapeutics. Proud of the Crescent team for their dedication to our bold vision of building the next leading biotech oncology company.

[Crescent Biopharma @crescent_bio]

Our update today, including our partnership with Kelun-Biotech and progress across our portfolio, demonstrates our commitment to bringing the next wave of therapies to cancer patients.

Read our press releases:
https://t.co/vOzhHRgg4q
https://t.co/U32vndQ9cL

[Josh Brumm @BrummJosh]

Incredibly fortunate to work alongside such a talented and dedicated team!

[Crescent Biopharma @crescent_bio]

We’re building a leading oncology company with a culture that attracts bold innovators united by one mission: delivering transformative therapies for people living with cancer. Hear from our colleagues on what makes Crescent so special: https://t.co/cBIx66uHE9

#TeamCrescent

[Josh Brumm @BrummJosh]

Paul’s deep expertise and genuine passion for pioneering innovative therapies that can improve outcomes for people living with cancer, make him an incredible addition to Crescent. We’re fortunate to have Paul in this important role!

[Crescent Biopharma @crescent_bio]

Meet Paul Herszdorfer, Crescent’s VP, Head of Global Medical Affairs. With a decade of medical affairs experience in the biopharma industry, Paul will be instrumental in helping us to deliver the next standard of care in #oncology. Excited to have Paul on the Crescent team!

[Josh Brumm @BrummJosh]

Excited to have Elvis on our growing team as we work to bring potentially life-changing therapies for people with cancer.

[Crescent Biopharma @crescent_bio]

Meet Elvis Osei Tutu, PharmD, Crescent’s VP, Head of Regulatory Affairs. He brings deep experience in #oncology drug development, including leading global submissions & approvals. Thrilled to have him onboard, helping to deliver the next wave of transformative #cancer therapies.

[Josh Brumm @BrummJosh]

I’m delighted to have Tanya on the Crescent leadership team and playing an integral role in our efforts to advance therapeutics that have the potential to be life-changing for people with cancer.

[Crescent Biopharma @crescent_bio]

Meet Tanya Sengupta, Crescent’s EVP, Chief of Strategy & Operations. She brings extensive experience in portfolio strategy, oncology clinical operations and leading teams at all stages of drug development & commercialization. Thrilled to have Tanya onboard! #Leadership #Oncology

[Josh Brumm @BrummJosh]

Thrilled to have Jan joining Crescent and playing an integral role in our efforts to become a leader in delivering the next wave of therapies for cancer patients.

[Crescent Biopharma @crescent_bio]

Excited to welcome Jan Pinkas as Crescent’s CSO! He brings 20+ years in #oncology drug development with expertise in multiple modalities, including ADCs, and will be instrumental in driving innovation across our portfolio. Read more: https://t.co/bx855Q6XPM
#CancerResearch

[Josh Brumm @BrummJosh]

Great to be listed as “CBIO” on Nasdaq! This is an important milestone in our efforts to bring transformative therapies to cancer patients.

[Crescent Biopharma @crescent_bio]

We’re excited to be trading on Nasdaq as “CBIO"! Thank you to the Crescent team, our Board, shareholders and many others who have supported our vision of building a world leading oncology company.
$CBIO
#CancerResearch
#Oncology

[Josh Brumm @BrummJosh]

Thrilled to have completed our merger and proud to be part of this Crescent team that is dedicated to advancing therapies that could truly make a difference in the lives of people facing cancer.

[Crescent Biopharma @crescent_bio]

We completed the closing of our merger with GlycoMimetics and previously announced $200M financing. Crescent to trade on NASDAQ as “CBIO”. We’re excited to bring the next wave of therapies for cancer patients. Learn more: https://t.co/M0GzwYt1XN
$CBIO

[Josh Brumm @BrummJosh]

Thrilled to have David Lubner joining Crescent’s Board – an industry veteran with deep experience in finance, corporate strategy & operations. Look forward to working with him on our exciting journey to build a world leading oncology company. Read more: https://t.co/KjbsPG9NGn

[Josh Brumm @BrummJosh]

Excited to be joining Crescent as CEO and to be part of building a world leading oncology company. I look forward to working with this accomplished team that has a proven track record & shared commitment to delivering life-changing therapies for patients. https://t.co/5YQv8VZgiy

[Josh Brumm @BrummJosh]

Grateful to join the Forbion Family and build great companies with friends and colleagues that value culture, management teams and delivering on the promise of bringing transformational therapies to patients - impacting the future of medicine.